1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics in European Union, November 2019

Cancer Analysis & Statistics in European Union, November 2019

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Datamonitor Healthcare

All regions

data types

1-30 of 62 reports

NHL: Follicular Lymphoma Forecast and Market Analysis to 2025

NHL: Follicular Lymphoma Forecast and Market Analysis to 2025

  • $ 22000
  • Industry report
  • April 2018

Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL). It is the second most common type of NHL after diffuse large B-cell lymphoma (DLBCL), and accounts for more than 20% of ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034

NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034

  • $ 22000
  • Industry report
  • April 2018

Mantle cell lymphoma (MCL) is a rare form of B-cell non-Hodgkin’s lymphoma (NHL), accounting for 3–6% of new NHL cases. The term MCL derives from the growth pattern of the lymphoma, with tumor cells ...

  • Industries : Cancer, Pathology
  • Countries : European Union, United States, Japan
NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034

  • $ 22000
  • Industry report
  • April 2018

Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes. This cancer is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for about one-third ...

  • Industries : Cancer, Pathology, Medical Biotechnology
  • Countries : United States, Japan, European Union
Ovarian Cancer Pricing, Reimbursement, and Access

Ovarian Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • March 2018

Ovarian cancer medicines have traditionally been subject to low restrictions, as most patients usually start and remain on inexpensive platinum-based therapies. However, beginning with the launch of vascula ...

  • Industries : Therapy
  • Countries : United States, European Union
Renal cell cancer (RCC) disease forecast and market analysis to 2035

Renal cell cancer (RCC) disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • February 2018

DISEASE OVERVIEWRenal cell cancer (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Prostate Cancer Disease Coverage Forecast and Market Analysis to 2024

Prostate Cancer Disease Coverage Forecast and Market Analysis to 2024

  • $ 22000
  • Industry report
  • January 2018

DISEASE OVERVIEWProstate cancer is a hormonally fueled disease, and the most common form of cancer found in males. Consequently, there is a high incentive for drug development in this indication due to ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Drug Analysis: ipatasertib

Drug Analysis: ipatasertib

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewIpatasertib (Roche) is a highly selective, ATP-competitive Akt inhibitor that preferentially targets active, phosphorylated Akt. Akt is dysregulated in a number of malignancies through loss ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug Analysis: apalutamide

Drug Analysis: apalutamide

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewApalutamide (Johnson and Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug Overview: Xtandi

Drug Overview: Xtandi

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewXtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits ...

  • Industries : Cancer
  • Countries : United States, Japan, European Union
Drug Analysis: Tecentriq

Drug Analysis: Tecentriq

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewTecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
Drug Analysis: Xofigo

Drug Analysis: Xofigo

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewXofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of increased ...

  • Industries : Cancer
  • Countries : United States, Japan, European Union
Drug Analysis: Zytiga

Drug Analysis: Zytiga

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewZytiga (abiraterone acetate; Johnson and Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Drug Overview: Jevtana

Drug Overview: Jevtana

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewJevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Drug Analysis: Xtandi

Drug Analysis: Xtandi

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewXtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits ...

  • Industries : Cancer
  • Countries : United States, Japan, European Union
Drug Analysis: Rubraca

Drug Analysis: Rubraca

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewRubraca (rucaparib) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor developed by Clovis Oncology for the treatment of recurrent ovarian cancer patients with known BRCA mutations ...

  • Industries : Therapy, Cancer, Pathology, Oncology
  • Countries : United States, European Union
Drug Overview: apalutamide

Drug Overview: apalutamide

  • $ 10000
  • Industry report
  • January 2018

Drug Overview Apalutamide (Johnson&Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug Overview: ipatasertib

Drug Overview: ipatasertib

  • $ 10000
  • Industry report
  • January 2018

Drug Overview Ipatasertib (Roche) is a highly selective, ATP-competitive Akt inhibitor that preferentially targets active, phosphorylated Akt. Akt is dysregulated in a number of malignancies through loss ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug Analysis: Jevtana

Drug Analysis: Jevtana

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewJevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) ...

  • Industries : Therapy, Cancer
  • Countries : United States, Japan, European Union
Drug Analysis: darolutamide

Drug Analysis: darolutamide

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewDarolutamide is a non-steroidal oral androgen receptor (AR)antagonist in development by Bayer for the treatment of prostate cancer. Darolutamide potently inhibits the binding of androgens ...

  • Industries : Therapy, Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug Analysis: DCVAC/PCa

Drug Analysis: DCVAC/PCa

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewDCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: Masitinib

Drug Analysis: Masitinib

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewMasitinib (AB Science) is an oral tyrosine kinase inhibitor being developed by AB Science. It targets a number of receptor tyrosine kinases including c-Kit, fibroblast growth factor recepto ...

  • Industries : Cancer, Pathology, Medical Biotechnology
  • Countries : European Union, United States
Drug Overview: Tecentriq

Drug Overview: Tecentriq

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewTecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
Drug Overview: Masitinib

Drug Overview: Masitinib

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewMasitinib (AB Science) is an oral tyrosine kinase inhibitor being developed by AB Science. It targets a number of receptor tyrosine kinases including c-Kit, fibroblast growth factor recepto ...

  • Industries : Cancer, Pathology, Medical Biotechnology
  • Countries : European Union, United States
Drug Overview: DCVAC/PCa

Drug Overview: DCVAC/PCa

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewDCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Overview: Xofigo

Drug Overview: Xofigo

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewXofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of increased ...

  • Industries : Cancer
  • Countries : United States, Japan, European Union
Drug Overview: Zytiga

Drug Overview: Zytiga

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewZytiga (abiraterone acetate; Johnson&Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Drug Overview: darolutamide

Drug Overview: darolutamide

  • $ 10000
  • Industry report
  • January 2018

Drug Overview Darolutamide is a non-steroidal oral androgen receptor (AR)antagonist in development by Bayer for the treatment of prostate cancer. Darolutamide potently inhibits the binding of androgens ...

  • Industries : Therapy, Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug Overview: Rubraca

Drug Overview: Rubraca

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewRubraca (rucaparib) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor developed by Clovis Oncology for the treatment of recurrent ovarian cancer patients with known BRCA mutations ...

  • Industries : Therapy, Cancer, Pathology, Oncology
  • Countries : United States, European Union
Drug analysis: Erbitux

Drug analysis: Erbitux

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewErbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) is a chimeric monoclonal antibody (MAb) that binds to the extracellular domain of epidermal growth factor receptor (EGFR). The ...

  • Industries : Therapy, Medical Biotechnology
  • Countries : United States, Japan, European Union
Drug analysis: Lonsurf

Drug analysis: Lonsurf

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewLonsurf ([trifluridine + tipiracil]; Otsuka/Servier) is an oral combination drug with both anti-angiogenic and cytotoxic effects. It is composed of trifluridine, an antineoplastic nucleoside ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on